Last reviewed · How we verify
An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers
The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 8 |
| Start date | 2008-02 |
| Completion | 2008-09 |
Conditions
- Anxiety
Interventions
- AZD6280
- (11C) flumazenil
Primary outcomes
- Positron emission tomography using the radioligand (11C) flumazenil — 4 times per subject
Countries
Sweden